From Swiss Stakes to Fresh Takes: Megasoft’s $15 Million Exit from Extrovis AG

Image Source: CNBCTV18

Megasoft Ltd informed on July 1, 2025, that the company board has sanctioned the sale of the company's entire 36.52% stake in Swiss group company Extrovis AG to Refex Life Sciences Pvt Ltd for $15 million (approximately ₹128.4 crore) based on the exchange rate fluctuations.

Key Highlights:

The transaction is not a related-party transaction since Refex Life Sciences is not controlled by the group companies or promoters of Megasoft.
The payment will be in one or more tranches, and the SPA is outstanding for signature.
Megasoft will seek shareholder approval by post ballot before completing the deal.
Extrovis AG was a subsidiary company of Megasoft since 2023, and Megasoft had previously acquired a 40% stake for about $16.78 million in various tranches fulfilled by January 2023.
Extrovis AG's activities have affected Megasoft's consolidated financials only by proportionate loss recognition, without any contribution on a standalone basis.
Megasoft shares fell to the lower circuit after the news and closed 2% down at ₹107.27 on the NSE.

Background:

Megasoft had acquired Swiss pharmaceutical discovery and pharma APIs firm Extrovis AG as part of its pharma segment diversification. The acquisition began in 2022 and was finished by early 2023, when the company had 40% stake before deciding to sell a major portion of this equity now.

Market Impact:

The transaction is a strategic one for Megasoft, perhaps to centralize operations or reallocate capital, while the buyer, Refex Life Sciences, may aim to increase its presence in the life sciences and pharma sector.

Source: CNBC-TV18, TradingView, Market Screener, Official filings of Megasoft Ltd